Close
RNS Number : 6451N
Alliance Pharma PLC
01 October 2021
 

For immediate release

1 October 2021

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 565,776 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.

Peter Butterfield, Chief Executive Officer, has been awarded 29,182 approved and 139,943 unapproved share options under the Company's 2015 Share Option Plan; and, 180,970 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

Andrew Franklin, Chief Financial Officer, has been awarded 115,000 unapproved share options under the Company's 2015 Share Option Plan; and, 100,681 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 102.8p, being the closing mid-market price on 28th of September 2021, and become exercisable on 29th of September 2024, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 29th of September 2024.

The vesting of these awards is subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

Name

Share Options granted

Total no. of options over ordinary shares now held

Peter Butterfield

350,095

3,345,548

Andrew Franklin

215,681

2,069,192

 

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

 

 

 

 

Notification and public disclosure of transactions by person discharging managerial responsibilities.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr Peter Butterfield

2

Reason for the notification

a)

Position/status

Chief Executive Officer - PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1.0 pence each

 

 

 

ISIN: GB0031030819

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Exercise Price (p)

No. of share options

102.8p

169,125

Nil

180,970

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

Grant of 169,125 options to acquire shares of 1p each at £1.028 per share at an aggregate exercise value of £173,860.50.

Grant of 180,970 options to acquire ordinary shares of 1 pence each at nil-cost.

 

 

 

f)

Date of the transaction

29 September 2021

g)

Place of the transaction

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr Andrew Franklin

2

Reason for the notification

a)

Position/status

Chief Financial Officer - PDMR

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1.0 pence each

 

 

 

ISIN: GB0031030819

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Exercise Price (p)

No. of share options

102.8p

115,000

Nil

100,681

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

Grant of 115,000 options to acquire shares of 1 pence each at £1.028 per share at an aggregate exercise value of £118,220.

Grant of 100,681 options to acquire ordinary shares of 1 pence each at nil-cost.

 

f)

Date of the transaction

29 September 2021

g)

Place of the transaction

Outside of trading venue

 

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCVBLFXFKLLBBE